# Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

Source: https://onco.cc/trials/nct04404595/  
OnCo record `nct04404595` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CT041 in gastric & gastro-oesophageal junction cancer and pancreatic ductal adenocarcinoma, run by CARsgen Therapeutics Co., Ltd., active and no longer recruiting.

## Summary

Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers is a phase 1/2 interventional study registered as NCT04404595 by CARsgen Therapeutics Co., Ltd., with 110 participants enrolled, started 2020-10-23 and due to reach its primary completion in 2025-06-01. Interventions recorded: CT041.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04404595
- Phase: 1/2
- Setting: Open-label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects With Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers
- Sponsor: CARsgen Therapeutics Co., Ltd.
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT04404595: https://clinicaltrials.gov/study/NCT04404595

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [CARsgen Therapeutics](https://onco.cc/companies/carsgen/)

---
JSON: https://onco.cc/api/v1/entities/nct04404595.json